CONFIRM was a @-year , placebo-controlled study of the efficacy and safety of DMF @ mg twice ( BID ) or @ times daily ( TID ) in @,@ patients with relapsing-remitting multiple sclerosis ( RRMS ) ; subcutaneous glatiramer acetate @ mg once daily was included as an active reference comparator .